Lanadelumab’s impact on hereditary angioedema control and quality of life across disease activity subgroups
Andrea Zanichelli(IRCCS Policlinico San Donato), Inmaculada Martinez‐Saguer, Maureen Watt(La Jolla Institute for Immunology), Aleena Banerji(Massachusetts General Hospital), Daniel Nova Estepan(Takeda (United States)), Mauro Cancian(University of Padua), Stephen Betschel(University of Toronto), Paula J. Busse(Massachusetts General Hospital), Tamar Kinaciyan(Medical University of Vienna), Walter A. Wuillemin(University of Bern), H. James Wedner(Washington University in St. Louis), Irmgard Andresen(Takeda (Switzerland)), Emel Aygören‐Pürsün, Salomé Juethner(Takeda (United States)), Aharon Kessel(Technion – Israel Institute of Technology), Natalie Khutoryansky(Henry Ford Health System), Rémi Gagnon, M. Dawn Goodyear, Markus Magerl(Humboldt-Universität zu Berlin), Andreas Recke(University of Lübeck)
Cited by 10
Related Papers
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|504
Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients
|Allergy|2004|301
Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells
|Autoimmunity Reviews|2011|293
Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function
|The Journal of Immunology|2007|229